Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.21.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Income Statement [Abstract]    
Research and development expenses, net $ 20,935 $ 13,489
General and administrative expenses 9,323 8,718
Operating loss 30,258 22,207
Finance income, net (172) (1,644)
Loss before income tax 30,086 20,563
Income tax
Net Loss $ 30,086 $ 20,563
Basic and diluted loss per share of Common Stock $ 1.30 $ 3.66
Weighted average number of shares of Common Stock outstanding, basic and diluted 23,062,216 5,615,856